NCT06004245 2026-02-17
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting